Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
University of Kansas Medical Center
University of Kansas Medical Center
Alliance for Clinical Trials in Oncology
National University Hospital, Singapore
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
St. Joseph's Hospital and Medical Center, Phoenix
Assistance Publique - Hôpitaux de Paris
University of Nottingham
Avid Radiopharmaceuticals
University of Aarhus
National Cancer Institute (NCI)
Imperial College London
Turku University Hospital
University of Aberdeen
CHU de Reims
Assiut University
University of Virginia
Northwestern University
M.D. Anderson Cancer Center
Ottawa Hospital Research Institute
Assiut University
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
American College of Radiology Imaging Network
Assiut University
University of Aberdeen
Massachusetts General Hospital
AHS Cancer Control Alberta
Turku University Hospital
NHS Greater Glasgow and Clyde
Universitaire Ziekenhuizen KU Leuven
NHS Greater Glasgow and Clyde
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mahidol University
Odense University Hospital
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
National Cancer Institute (NCI)
Aposense Ltd.
University of Zurich
National Cancer Institute (NCI)
Aposense Ltd.
National Cancer Institute (NCI)
Naviscan PET Systems